منابع مشابه
GD_Itronix_Tadpole_Topaz_PCM053, 012-019 Focus.qxd
So what is the Tadpole Topaz and what does it have to offer? That would be a tough, rugged notebook computer with a large 15.1-inch 1400 x 1050 pixel sunlight-viewable display and enough performance to power through very demanding applications, delivering stunning graphics performance in the process. While the Topaz is compact and lightweight by military standards, that still means a 12-pound p...
متن کاملX98-019.CHP:Corel VENTURA
The impact of increasing the number of crosses per parent (k) on the efficiency of roguing seed orchards (backwards selection, i.e., reselection of parents) was examined by using Monte Carlo simulation. Efficiencies were examined in light of advanced-generation Douglas-fir (Pseudotsuga menziesii (Mirb.) Franco) tree improvement programs where information is available from previous generations, ...
متن کاملItronix_GD_DynaVue.qxd:PCM053, 012-019 Focus.qxd
Don’t you just hate it when some marketing guy labels something as “ultimate”? Well, I’ve found something that really should be labeled as “ultimate”. It’s General Dynamics (GD) Itronix’ brand-new DynaVue outdoor-readable touch-screen display technology. The American Heritage Dictionary defines “ultimate” as “representing or exhibiting the greatest possible development or sophistication”, and t...
متن کاملOral food desensitisation: are the patients safe after the end of protocol?
Results Before desensitization protocol all patients had presented anaphylaxis, being 9 in the last year, regarding accidental ingestion. Mean serum level of specific IgE to milk and casein were 55.24 and 47.3, respectively. From all well succeeded patients (200ml of milk at the end of protocol,) 9 patients still presented isolated reactions, being 3 Grade 1, 1 Grade 2, 0 grade 3, 5 Grade 4, 0 ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Hospital Pharmacy
سال: 2013
ISSN: 2047-9956,2047-9964
DOI: 10.1136/ejhpharm-2013-000276.285